Current results from therapy of testicular tumors

Boctor, Z. N.; Kurohara, Samuel S.; Badib, Ahmed O.; Murphy, Gerald P.

doi:10.1002/1097-0142(196911)24:5<870::aid-cncr2820240503>3.0.co;2-2

Cited by 21 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Adjuvant radiotherapy was the standard adjuvant treatment in clinical stage I seminoma patients for several decades [111]. The recurrence rate after modern radiation therapy is below 5%, and therefore equivalent to adjuvant carboplatin chemotherapy [100].…”

Section: Diagnostic Toolsmentioning

confidence: 99%

ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up

et al. 2018

View full text Add to dashboard Cite

The European Society for Medical Oncology (ESMO) consensus conference on testicular cancer was held on 3-5 November 2016 in Paris, France. The conference included a multidisciplinary panel of 36 leading experts in the diagnosis and treatment of testicular cancer (34 panel members attended the conference; an additional two panel members [CB and K-PD] participated in all preparatory work and subsequent manuscript development). The aim of the conference was to develop detailed recommendations on topics relating to testicular cancer that are not covered in detail in the current ESMO Clinical Practice Guidelines (CPGs) and where the available level of evidence is insufficient. The main topics identified for discussion related to: (1) diagnostic work-up and patient assessment; (2) stage I disease; (3) stage II-III disease; (4) post-chemotherapy surgery, salvage chemotherapy, salvage and desperation surgery and special topics; and (5) survivorship and follow-up schemes. The experts addressed questions relating to one of the five topics within five working groups. Relevant scientific literature was reviewed in advance. Recommendations were developed by the working groups and then presented to the entire panel. A consensus vote was obtained following whole-panel discussions, and the consensus recommendations were then further developed in post-meeting discussions in written form. This manuscript presents the results of the expert panel discussions, including the consensus recommendations and a summary of evidence supporting each recommendation. All participants approved the final manuscript.

show abstract

Section: Diagnostic Toolsmentioning

confidence: 99%

ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up

et al. 2018

View full text Add to dashboard Cite

show abstract

“…T h e interval since diagnosis varied from 0 months to more than 3 years, with a median interval of 5 months. Previous surgical therapy included biopsy of testis or peripheral lymph node (9), orchiectomy (57), orchiectomy and retroperitoneal node dissection (28), other tumor resection (3), and unspecified type of surgery (2). Previous radiation therapy had been administered to 55 patients.…”

Section: Methodsmentioning

confidence: 99%

Mithramycin (NSC 24559) therapy of testicular tumors

Hill¹,

Sedransk²,

Rochlin³

et al. 1972

Cancer

View full text Add to dashboard Cite

A Phase II clinical trial of mithramycin was performed in 99 patients with evaluable metastatic testicular tumors. Patients received 25 μg/kg/day until therapy was stopped because of toxicity. In the absence of persistent toxicity or progression, subsequent courses were begun 4 weeks after discontinuance of the previous course. In the 74 patients with acceptable studies, responses occurred in 26% (5 complete responses and 14 partial responses). Complete responses were persistent for periods of up to 77+ months, and three patients with complete responses were alive and well at last report. Death occurred within 3 weeks after the onset of therapy in 10 patients, and coagulopathy was present in five of these patients. Toxicity of mithramycin was relatively unpredictable, and patients who exhibited severe toxicity received relatively little benefit from therapy. Responses were most common in young men with asymptomatic metastatic disease, and complete responses occurred only in patients with embryonal carcinoma.

show abstract

“…Bei den malignen Teratomen ist wegen der geringeren Strahlensensibilität die Bestrahlung als eine zusätzliche Maßnahme im Rahmen der koordinierten multidisziplinären Therapie anzusehen. Im pathologischen Stadium I (histologisch negatives Ergebnis der Lymphadenektomie) bewirkt die zusätzlich zur Semikastration und Lymphadenektomie durchgeführte Strahlentherapie keine Verbesserung der Fünfjahres-Cberlebensraten (3,41). In den anderen Stadien wird sie als primäre Behandlungsmaßnahme zunehmend zugunsten der Zytostatika-Applikation verlassen, da die erforderliche Dosis (5000 bis 6000 rad Herddosis in S bis 6 Wochen) zu einer erheblichen Belastung der im Strahiengebiet liegenden Organe, vor allem des Knochenmarks, führt.…”

Section: Radiologische Behandlungunclassified

Therapie der Hodentumoren

Höffken¹,

Cg²

1977

Dtsch med Wochenschr

View full text Add to dashboard Cite

Current results from therapy of testicular tumors

Cited by 21 publications

References 8 publications

ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up

ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up

Mithramycin (NSC 24559) therapy of testicular tumors

Therapie der Hodentumoren

Contact Info

Product

Resources

About